Managing pain in inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 7, Issue 9, 2011, Pages 592-601

  Docherty, Michael J ^a   Jones III, R Carter W ^b   Wallace, Mark S ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

Inflammatory bowel disease; Irritable bowel syndrome; Management; Pain

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; C REACTIVE PROTEIN; CITALOPRAM; DESIPRAMINE; DICYCLOVERINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; HYOSCYAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PARACETAMOL; PAROXETINE; PREGABALIN; SERTRALINE; TRAMADOL; VENLAFAXINE;

ABSCESS; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTHRITIS; BODY WEIGHT; CHOLELITHIASIS; COLITIS; CONFUSION; CONSTIPATION; DIAPHORESIS; DIARRHEA; DIZZINESS; ENTERITIS; ENTEROPATHY; ERYTHEMA NODOSUM; GASTRITIS; HEADACHE; HUMAN; HYPOTENSION; INSOMNIA; INTESTINE FISTULA; IRITIS; NARCOTIC BOWEL SYNDROME; NAUSEA; NEPHROLITHIASIS; PAIN ASSESSMENT; PATIENT ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PSYCHOTHERAPY; PYODERMA GANGRENOSUM; REVIEW; SACROILIITIS; SEDATION; SEIZURE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; URINE RETENTION; UVEITIS; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 81855180518     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Simrén M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396. (Pubitemid 34160766)
2. Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:3168-3177.
3. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4:1491-1501.
4. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530. (Pubitemid 34117002)
5. De Rooy EC, Toner BB, Maunder RG, et al. Concerns of patients with inflammatory bowel disease: results from a clinical population. Am J Gastroenterol. 2001;96:1816-1821.
6. Janke K-H, Klump B, Gregor M, et al. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:272-286. (Pubitemid 40439682)
7. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106:287-296. (Pubitemid 24041204)
8. Lix LM, Graff LA, Walker JR, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1575-1584.
9. Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:778-788.
10. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
11. Farrokhyar F, Marshall JK, Easterbrook B, et al. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis. 2006;12:38-46. (Pubitemid 43032450)
12. Mikocka-Walus AA, Turnbull DA, Andrews JM, et al. The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:475-483. (Pubitemid 352033281)
13. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15:1105-1118.
14. Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis. 2006;12:697-707. (Pubitemid 44253753)
15. Walker EA, Gelfand MD, Gelfand AN, et al. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry. 1996;18:220-229. (Pubitemid 26251507)
16. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163-173.
17. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol. 2010;105:1789-1794.
18. Grover M, Herfarth H, Drossman DA. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009;7:48-53.
19. Long MD, Drossman DA. Inflammatory bowel disease, irritable bowel syndrome, or what?: a challenge to the functional-organic dichotomy. Am J Gastroenterol. 2010;105:1796-1798.
20. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16:1248-1257.
21. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. Cell. 2009;139:267-284.
22. Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev. 2009;89:707-758.
23. Li D, Ren Y, Xu X, et al. Sensitization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related Peptide driven by dorsal root reflexes. J Pain. 2008;9:1155-1168.
24. Ikeda H, Heinke B, Ruscheweyh R, et al. Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. Science. 2003;299:1237-1240. (Pubitemid 36237466)
25. Heinricher MM, Tavares I, Leith JL, et al. Descending control of nociception: specificity, recruitment and plasticity. Brain Res Rev. 2009;60:214-225.
26. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 2002;25:319-325. (Pubitemid 34667014)
27. Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16:1277-1283.
28. Su X, Gebhart GF. Mechanosensitive pelvic nerve afferent fibers innervating the colon of the rat are polymodal in character. J Neurophysiol. 1998;80:2632-2644. (Pubitemid 28546191)
29. Xu L, Gebhart GF. Characterization of mouse lumbar splanchnic and pelvic nerve urinary bladder mechanosensory afferents. J Neurophysiol. 2008;99:244-253.
30. Brierley SM, Jones RCW, Gebhart GF, et al. Splanchnic and pelvic mechanosensory afferents signal different qualities of colonic stimuli in mice. Gastroenterology. 2004;127:166-178. (Pubitemid 38962285)
31. Morgan C, Nadelhaft I, De Groat WC. The distribution of visceral primary afferents from the pelvic nerve to Lissauer's tract and the spinal gray matter and its relationship to the sacral parasympathetic nucleus. J Comp Neurol. 1981;201:415-440. (Pubitemid 11010912)
32. Zochling J, Van Der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/ EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65:423-432.
33. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387-1394.
34. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43:378-385. (Pubitemid 30395747)
35. Feagins LA, Cryer BL. Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig Dis Sci. 2010;55:226-232.
36. Kefalakes H, Stylianides TJ, Amanakis G, et al. Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: myth or reality? Eur J Clin Pharmacol. 2009;65:963-970.
37. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-516. (Pubitemid 17149770)
38. Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicylate. Br Med J. 1984;288:794. (Pubitemid 14117971)
39. Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal antiinflammatory drugs. Br Med J. 1984;288:238.
40. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981;57:297-299. (Pubitemid 11114434)
41. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949-1954.
42. Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619-622. (Pubitemid 27278329)
43. Bonner GF, Walczak M, Kitchen L, et al. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:1946-1948. (Pubitemid 30629291)
44. Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:751-757. (Pubitemid 39545220)
45. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol. 2010;105:1994-2002.
46. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196-202. (Pubitemid 43199690)
47. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
48. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124:288-292. (Pubitemid 36169245)
49. Mahadevan U, Loftus EV, Tremaine WJ, et al. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-914. (Pubitemid 34408247)
50. Sandborn WJ, Stenson WF, Brynskov J, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-211. (Pubitemid 43199691)
51. Gleeson MH, Davis AJM. Non-steroidal anti-inflammatory drugs, aspirin and newly diagnosed colitis: a case-control study. Aliment Pharmacol Ther. 2003;17:817-825. (Pubitemid 36418879)
52. Solomon SD, McMurray JJV, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080. (Pubitemid 40365348)
53. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102. (Pubitemid 40365350)
54. Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of opioids for noncancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
55. Jones JL, Loftus EV. Avoiding the vicious cycle of prolonged opioid use in Crohn's disease. Am J Gastroenterol. 2005;100:2230-2232.
56. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953. (Pubitemid 37409712)
57. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10:147-159.
58. Ballantyne JC. Opioid analgesia: perspectives on right use and utility. Pain Physician. 2007;10:479-491. (Pubitemid 46971301)
59. Kaplan MA, Korelitz BI. Narcotic dependence in inflammatory bowel disease. J Clin Gastroenterol. 1988;10:275-278.
60. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229.
61. Edwards JT, Radford-Smith GL, Florin THJ. Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics. J Gastroenterol Hepatol. 2001;16:1235-1238. (Pubitemid 34088270)
62. Hanson KA, Loftus EV, Harmsen WS, et al. Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study. Inflamm Bowel Dis. 2009;15:772-777.
63. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130.
64. Grunkemeier DMS, Cassara JE, Dalton CB, et al. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin Gastroenterol Hepatol. 2007;5:1126-1139. (Pubitemid 47488969)
65. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
66. Madl C, Druml W. Gastrointestinal disorders of the critically ill. Systemic consequences of ileus. Best Pract Res Clin Gastroenterol. 2003;17:445-456.
67. Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2008;2:14-18.
68. Moore TM, Jones T, Browder JH, et al. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. Pain Med. 2009;10:1426-1433.
69. Clinical Bridges. Opioid risk tool. http://www.painknowledge.org/ physiciantools/.
70. Sullivan MD, Von Korff M, Banta-Green C, et al. Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain. Pain. 2010;149:345-353.
71. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601.
72. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97:S7-S26.
73. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108:65-72. (Pubitemid 30058279)
74. Drossman DA, Toner B, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31. (Pubitemid 36799103)
75. Levy RL, Olden KW, Naliboff BD, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology. 2006;130:1447-1458.
76. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1:219-228. (Pubitemid 37248073)
77. Ladabaum U, Sharabidze A, Levin TR, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8:42-48.
78. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99:914-920. (Pubitemid 39090223)
79. Ford AC, Talley NJ, Schoenfeld PS, et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and metaanalysis. Gut. 2009;58:367-378.
80. Mikocka-Walus AA, Turnbull DA, Moulding NT, Wilson IG, Andrews JM, Holtmann GJ. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health. 2006;2:24.
81. Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion. Gastroenterology. 2001;121:1260-1261.
82. Kane SV, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology. 2003;125:1290.
83. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903-907.
84. Houghton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007;56:1218-1225. (Pubitemid 47300421)
85. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22:981-988. (Pubitemid 41634880)
86. Heymann-Mönnikes I, Arnold R, Florin I, et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol. 2000;95:981-994. (Pubitemid 30196735)
87. Zijdenbos IL, De Wit NJ, Van Der Heijden GJ, et al. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009:CD006442.
88. Grace WJ, Wolff HG. Treatment of ulcerative colitis. JAMA. 1951;146: 981-987.
89. Mackner LM, Clough-Paabo E, Pajer K, et al. Psychoneuroimmunologic factors in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:849-857.
90. Von Wietersheim J, Kessler H. Psychotherapy with chronic inflammatory bowel disease patients: a review. Inflamm Bowel Dis. 2006;12:1175-1184. (Pubitemid 44847475)
91. Deter H-C, Keller W, Von Wietersheim J, et al. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm Bowel Dis. 2007;13:745-752.
92. Jones RCW, Xu L, Gebhart GF. The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci. 2005;25:10981-10989. (Pubitemid 41692628)
93. Jones RCW, Otsuka E, Wagstrom E, et al. Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse. Gastroenterology. 2007;133:184-194. (Pubitemid 47031128)
94. De Schepper HU, De Winter BY, Van Nassauw L, et al. TRPV1 receptors on unmyelinated C-fibres mediate colitis-induced sensitization of pelvic afferent nerve fibres in rats. J Physiol. 2008;586:5247-5258.
95. Miranda A, Nordstrom E, Mannem A, et al. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. Neuroscience. 2007;148:1021-1032. (Pubitemid 47419190)
96. Yiangou Y, Facer P, Dyer NH, et al. Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet. 2001;357:1338-1339. (Pubitemid 32441536)
97. Chan CLH, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet. 2003;361:385-391. (Pubitemid 36164972)
98. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut. 2010;59:767-774.
99. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009;78:211-216.
100. Dmitrieva N, McMahon SB. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain. 1996;66:87-97. (Pubitemid 26247028)
101. Bielefeldt K, Ozaki N, Gebhart GF. Role of nerve growth factor in modulation of gastric afferent neurons in the rat. Am J Physiol Gastrointest Liver Physiol. 2003;284:G499-G507. (Pubitemid 36227898)
102. Di Mola FF, Friess H, Zhu ZW, et al. Nerve growth factor and Trk high affinity receptor (TrkA) gene expression in inflammatory bowel disease. Gut. 2000;46:670-679.
103. Johansson M, Norrgård O, Forsgren S. Study of expression patterns and levels of neurotrophins and neurotrophin receptors in ulcerative colitis. Inflamm Bowel Dis. 2007;13:398-409. (Pubitemid 46668244)
104. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363:1521-1531.
105. Sengupta JN, Su X, Gebhart GF. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology. 1996;111:968-980. (Pubitemid 26327599)
106. Sengupta JN, Snider A, Su X, et al. Effects of kappa opioids in the inflamed rat colon. Pain. 1999;79:175-185. (Pubitemid 29076752)
107. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:239-249. (Pubitemid 351861967)
108. McGarrity TJ, Peters DJ, Thompson C, et al. Outcome of patients with chronic abdominal pain referred to chronic pain clinic. Am J Gastroenterol. 2000;95:1812-1816. (Pubitemid 30485023)
109. Giordano J, Schatman ME. An ethical analysis of crisis in chronic pain care: facts, issues and problems in pain medicine; part I. Pain Physician. 2008;11:483-490.